Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More

uniQure Announces Completion Of Additional Patient Procedures Following Positive Recommendation From Data Safety Monitoring Board In Phase I/II Clinical Trial Of AMT-130 For The Treatment Of Huntington’s Disease

uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that two additional patient procedures have been completed in the

QURE